NCATS SBIR Phase I
Supports small businesses testing translational science tools and technologies through early feasibility and commercialization groundwork.
The National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health, administers SBIR Phase I grants (R43) to fund small US businesses seeking to establish the technical merit and feasibility of translational science innovations. NCATS focuses on four priority topic areas: preclinical drug discovery and development, biomedical and clinical and health …
Feasibility research for small businesses in NCATS priority areas: preclinical drug discovery, biomedical and health research informatics, clinical and implementation research, and rare disease.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see the timeline
Guides for this application
All guides →SBIR/STTR Grants for Deeptech Startups
A practical guide to SBIR and STTR grants for deeptech startups, including agency fit, Phase I and II logic, eligibility, budgets, and review criteria.
DocumentsNIH Biosketch Guide: Format, SciENcv Steps, and Examples
Learn what an NIH biosketch is, how the format works, what to prepare for SciENcv, and how startup teams should avoid common biosketch mistakes.
Write proposalHow to Write a Specific Aims Page
Learn how to write a specific aims page for NIH, SBIR-adjacent, and translational R&D grants, with structure, reviewer logic, examples, and common mistakes.
Where to applyGrants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
More from NCATS
All grants from this funder →Oligonucleotide Toxicity (OligoTox) Open Data Challenge
🇺🇸NCATS · United States
Pays cash prizes for public datasets that help predict oligonucleotide drug toxicity in human cells.
NCATS Clinical Trial Readiness for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies generating natural history data, biomarkers, and outcome measures needed to design clinical trials for rare diseases.
NCATS STTR Phase I
🇺🇸NCATS · United States
Funds U.S. small businesses and their nonprofit research partners to conduct feasibility studies on translational science innovations toward commercialization.
NCATS STTR Phase II
🇺🇸NCATS · United States
Funds U.S. small businesses and their nonprofit research partners to continue and expand translational R&D begun in STTR Phase I toward a commercial product.
NCATS SBIR Phase II
🇺🇸NCATS · United States
Backs small businesses scaling proven translational findings into applied solutions and early market readiness.
NCATS Preclinical Proof of Concept Studies for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies conducting preclinical efficacy studies to advance therapeutic candidates for rare diseases toward IND applications.
Similar grants
Browse the directory →
NSF SBIR Phase I
🇺🇸NSF · United States
Funds United States deep-tech startups demonstrating scientific feasibility of novel science and engineering innovations.
NIH SBIR Phase I
🇺🇸NIH SEED · United States
Funds early stage United States biomedical teams through NIH seed support for feasibility work on prototype ready ideas.
NIH SBIR Phase I (Omnibus)
🇺🇸NIH · United States
Funds United States small businesses advancing biomedical and behavioral-health innovations through early technical validation.
NEI SBIR Phase I — Feasibility
🇺🇸NEI · United States
Supports United States. small businesses testing vision concepts through feasibility-focused grants.
NSF STTR Phase I
🇺🇸NSF · United States
Funds United States deep-tech startups partnering with nonprofit research institutions for early-stage feasibility studies.
NIA SBIR Phase I
🇺🇸NIA · United States
Supports small businesses developing aging and memory technologies at the feasibility stage.